Portal de Periódicos da CAPES

Role of reoperation in recurrence of adrenal cortical carcinoma: Results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma

1997; Elsevier BV; Volume: 122; Issue: 6 Linguagem: Inglês

10.1016/s0039-6060(97)90229-4

1532-7361

Rocco Bellantone, Angela Ferrante, Mauro Boscherini, Celestino Pio Lombardi, Pierfilippo Crucitti, F Crucitti, Gennaro Favia, D Borrelli, L Boffi, Lorenzo Capussotti, Giovanni Carbone, M Casaccia, Antonio Cavallaro, Antonio Del Gaudio, G Dettori, V Di Giovanni, A Mazziotti, D Marrano, E Masenti, Paolo Miccoli, Fabio Mosca, Antonio Mussa, R Petronio, G Piat, U Ruberti, Giovanni Serio, Luigi Marzano,

Pituitary Gland Disorders and Treatments

Recurrence of adrenal cortical carcinoma (ACC) after radical surgery is a common finding. Although successful reoperations have been reported with encouraging results, most published experiences are anecdotal and based on few cases. We report the results of surgical treatment for recurrent ACC in a multiinstitutional series.One hundred eighty-eight cases of ACC were collected in a national registry. A complete follow-up was obtained in 179 cases. At initial diagnosis 92 patients had local disease (stage I or II). One hundred seventy patients underwent surgical treatment, considered radical in 140; in this group, recurrent disease was observed in 52 cases (37%) after a mean disease-free interval of 21.7 months.Adjuvant chemotherapy was ineffective in ameliorating the prognosis. The mean survival in 20 patients who underwent reoperation was significantly higher (15.85 +/- 14.9 months) than in nonreoperated cases (3.2 +/- 2.9 months). Five-year actuarial survival in reoperated patients is significantly better than in nonreoperated patients (49.7% versus 8.3%, respectively).Although the prognosis of this tumor is still poor, surgery is the only effective therapy; reoperation allows survival comparable to that observed in patients without recurrent disease. An aggressive strategy for recurrent ACC is advisable until prospective studies demonstrate a real effectiveness for chemotherapy.